Research ArticleMETABOLISM, TRANSPORT, AND PHARMACOGENOMICS
Aberrant Splicing Caused by Single Nucleotide Polymorphism c.516G>T [Q172H], a Marker of CYP2B6*6, Is Responsible for Decreased Expression and Activity of CYP2B6 in Liver
Marco H. Hofmann, Julia K. Blievernicht, Kathrin Klein, Tanja Saussele, Elke Schaeffeler, Matthias Schwab and Ulrich M. Zanger
Journal of Pharmacology and Experimental Therapeutics April 2008, 325 (1) 284-292; DOI: https://doi.org/10.1124/jpet.107.133306
Marco H. Hofmann
Julia K. Blievernicht
Kathrin Klein
Tanja Saussele
Elke Schaeffeler
Matthias Schwab
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleMETABOLISM, TRANSPORT, AND PHARMACOGENOMICS
Aberrant Splicing Caused by Single Nucleotide Polymorphism c.516G>T [Q172H], a Marker of CYP2B6*6, Is Responsible for Decreased Expression and Activity of CYP2B6 in Liver
Marco H. Hofmann, Julia K. Blievernicht, Kathrin Klein, Tanja Saussele, Elke Schaeffeler, Matthias Schwab and Ulrich M. Zanger
Journal of Pharmacology and Experimental Therapeutics April 1, 2008, 325 (1) 284-292; DOI: https://doi.org/10.1124/jpet.107.133306
Research ArticleMETABOLISM, TRANSPORT, AND PHARMACOGENOMICS
Aberrant Splicing Caused by Single Nucleotide Polymorphism c.516G>T [Q172H], a Marker of CYP2B6*6, Is Responsible for Decreased Expression and Activity of CYP2B6 in Liver
Marco H. Hofmann, Julia K. Blievernicht, Kathrin Klein, Tanja Saussele, Elke Schaeffeler, Matthias Schwab and Ulrich M. Zanger
Journal of Pharmacology and Experimental Therapeutics April 1, 2008, 325 (1) 284-292; DOI: https://doi.org/10.1124/jpet.107.133306
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement